Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595972 | 1.00 | CPB1 (0.47) | CPB1ALDH1A1GAASMN1; SMN2TSHR | |
| SCHEMBL9471139 | 0.89 | ALDH1A1 (0.52) | CPB1ALDH1A1GAASMN1; SMN2TSHR | |
| SCHEMBL31644552 | 0.86 | CPB1 (0.46) | CPB1ALDH1A1GAASMN1; SMN2TSHR | |
| SCHEMBL2992037 | 0.85 | ALDH1A1 (0.62) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL2992039 | 0.85 | ALDH1A1 (0.62) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL5007203 | 0.85 | ALDH1A1 (0.62) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL5011213 | 0.84 | ALDH1A1 (0.55) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL14010409 | 0.84 | ALDH1A1 (0.55) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL328917 | 0.83 | EPHX1 (0.57) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL20991956 | 0.81 | CPB1 (0.48) | CPB1ALDH1A1GAASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| US-20210346336-A1 | FURAN DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-11-11 | — | — | US | disclosed |
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-04-06 | — | — | US | disclosed |
| US-10844015-B2 | Pyridine dicarboxamide derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-20200291009-A1 | 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20190202786-A1 | PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-05-23 | — | — | US | disclosed |
| WO-2017202742-A1 | PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017174620-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | BRD3, BRD4, BRPF3 | CPB1 2736/4885ALDH1A1 2293/4885GAA 868/4885 |
| US-20200291009-A1 | 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD3 | CPB1 2266/4885ALDH1A1 958/4885GAA 840/4885 |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | CPB1 1949/4885ALDH1A1 1158/4885GAA 1606/4885 |
| US-20210346336-A1 | FURAN DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | CPB1 3443/4885ALDH1A1 2126/4885GAA 1171/4885 |
| US-20190202786-A1 | PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRPF3 | CPB1 1659/4885ALDH1A1 1717/4885GAA 1462/4885 |
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | BRD4, BRD3, BRPF3 | CPB1 2012/4885ALDH1A1 796/4885GAA 786/4885 |
| US-10844015-B2 | Pyridine dicarboxamide derivatives as bromodomain inhibitors | BRD4, BRD3, BRPF3 | CPB1 1659/4885ALDH1A1 1717/4885GAA 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.